A detailed history of Bell Investment Advisors, Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Bell Investment Advisors, Inc holds 79 shares of PCVX stock, worth $6,786. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79
Previous 79 -0.0%
Holding current value
$6,786
Previous $5,000 80.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$60.06 - $78.77 $600 - $787
10 Added 14.49%
79 $5,000
Q1 2024

May 08, 2024

BUY
$59.79 - $81.05 $478 - $648
8 Added 13.11%
69 $4,000
Q4 2023

Feb 14, 2024

BUY
$45.35 - $63.41 $90 - $126
2 Added 3.39%
61 $3,000
Q2 2023

Aug 09, 2023

BUY
$34.66 - $54.07 $1,594 - $2,487
46 Added 353.85%
59 $2,000
Q1 2023

May 10, 2023

BUY
$36.27 - $47.2 $471 - $613
13 New
13 $0
Q3 2022

Nov 09, 2022

BUY
$21.69 - $28.53 $607 - $798
28 New
28 $1,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.1B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Bell Investment Advisors, Inc Portfolio

Follow Bell Investment Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bell Investment Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bell Investment Advisors, Inc with notifications on news.